CELYAD SA/ADR (NASDAQ:CYAD)‘s stock had its “buy” rating restated by research analysts at William Blair in a research note issued to investors on Monday.

A number of other equities research analysts have also commented on CYAD. Zacks Investment Research lowered CELYAD SA/ADR from a “hold” rating to a “sell” rating in a research report on Monday, August 27th. Piper Jaffray Companies reduced their price objective on CELYAD SA/ADR to $51.00 and set an “overweight” rating for the company in a research note on Monday. Finally, HC Wainwright restated a “buy” rating and issued a $46.00 price objective on shares of CELYAD SA/ADR in a research note on Monday. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $43.80.

NASDAQ CYAD opened at $26.86 on Monday. The firm has a market capitalization of $276.43 million, a P/E ratio of -7.59 and a beta of 1.34. CELYAD SA/ADR has a 12 month low of $22.17 and a 12 month high of $53.49.

Large investors have recently made changes to their positions in the business. Wells Fargo & Company MN grew its stake in CELYAD SA/ADR by 1,109.0% in the 3rd quarter. Wells Fargo & Company MN now owns 6,045 shares of the company’s stock valued at $160,000 after purchasing an additional 5,545 shares during the period. Millennium Management LLC bought a new position in CELYAD SA/ADR in the 2nd quarter valued at $582,000. Stanley Laman Group Ltd. bought a new position in CELYAD SA/ADR in the 2nd quarter valued at $1,145,000. Finally, Victory Capital Management Inc. grew its stake in CELYAD SA/ADR by 2.8% in the 3rd quarter. Victory Capital Management Inc. now owns 621,162 shares of the company’s stock valued at $16,374,000 after purchasing an additional 17,160 shares during the period. Hedge funds and other institutional investors own 7.26% of the company’s stock.


Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.

Read More: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for CELYAD SA/ADR (NASDAQ:CYAD)

Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.